Hello, and welcome back to The Kable for the last time this week. We have a lot of news to cover today, including a wrap-up of the week so far.
First up, US biotech Scynexis has one marketed product: Brexafemme, a novel antifungal approved to treat vaginal yeast infections. Now GSK has acquired global rights to the drug with a $90 million upfront payment…
💉 Africa CDC launches outbreak warning system; US FDA launches Lupus Research Alliance; GSK launches attack on yeast infections
#309 | Moderna’s first African mRNA site; Emerging biopharmas put up R&D fight; AMR a population-wide plight
